Neurological · MAG-NEU-02 · v2
Several small placebo-controlled trials report that people taking magnesium rate their sleep as somewhat better than people taking a dummy pill ([1],[2],[4],[6]). The improvements tend to be modest and sit close to the line of being explainable by chance ([6],[4]). When sleep is measured objectively with a tracking device rather than by questionnaire, the benefit often disappears ([3]). The single largest real-world study, following thousands of people over years, found no reliable link and even a hint of poorer sleep and more night cramps among magnesium users ([13]). The trials also used many different magnesium products in different groups of people, and some were run by the companies selling them, so the panel treated the overall picture as a genuine but weak and uneven signal.
Seven controlled trials report magnesium improving subjective sleep quality versus a comparator ([1],[2],[4],[5],[6],[10],[12]), with reported effects such as a 32% versus 16% improvement (p=0.034) in [4] and an ISI reduction of -3.9 versus -2.3 (p=0.049, Cohen's d=0.2) in [6]. However, [3] found improvement on sleep-related impairment (p=0.043) but no group difference on sleep disturbances (p=0.316), restorative sleep (p=0.439), or objective ring measures. Direct nulls appear in [7], where magnesium had no effect on sleep quality in PCOS (p=0.85), and in the large CoLaus|PsyColaus cohort [13] (N=3,887), which found no consistent association and a trend toward poorer sleep. The interventions span L-threonate ([1],[3]), bisglycinate ([6]), oxide ([5],[7]), a Food-Grown product ([4]), and saffron ([8]) or melatonin ([9]) combinations. The contested point: The evidence divides on whether the subjective questionnaire gains reflect a real physiological effect: [3] recorded a single subjective win alongside no objective sleep difference, and the largest sample [13] contradicts the trial-level signal outright. The panel treated the modest, mainly subjective RCT benefit as offset by these null objective and observational findings.
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Magnesium, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim treats 'magnesium' as one intervention, but the corpus pools L-threonate, bisglycinate, oxide, Food-Grown and combination products with different bioavailability; efficacy of one form cannot license a blanket claim.
Objective and subjective results diverge: [3] found no group difference on Oura ring sleep outcomes despite a single subjective win, suggesting reporting artefact rather than a physiological effect.
Where it remains uncertain. Objective measures often show no difference ([3]) and the largest real-world study finds no association with a trend to poorer sleep ([13]).
Aleatory
Reported benefits are small and close to chance ([6] Cohen's d=0.2, p=0.049; [4] p=0.034), so random variation can swamp the signal.
Epistemic
L-threonate, bisglycinate, oxide, and Food-Grown products ([1],[3],[4],[5],[6],[7]) differ in bioavailability; no head-to-head establishes which, if any, drives benefit.
Inferential
[3] found improved subjective sleep-related impairment (p=0.043) but no objective ring difference, so inferring a physiological sleep effect from questionnaires is uncertain.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Supports: objective and subjective sleep improvement with magnesium-L-threonate in self-reported poor sleepers.
“From objective Oura ring measurements, MgT significantly (p < 0.05) improved vs placebo deep sleep score, REM sleep score, light sleep time”
Panel auditInternal validity: medium · scope of inference: Middle-aged adults with self-reported (non-clinical) sleep problems taking magnesium L-threonate specifically.Key limitations: small sample · magnesium L-threonate only · short duration · self-selected sleep complaints
Counter: mostly null on sleep endpoints, including no objective ring differences, despite a single significant subjective measure.
“there was a greater improvement in sleep-related impairment (p = 0.043), but no group differences in changes in sleep disturbances (p = 0.316), restorative sleep (p = 0.439)”
Panel auditInternal validity: medium · scope of inference: Healthy younger adults (18-45) with self-reported dissatisfied sleep taking magnesium L-threonate.Key limitations: mixed/split sleep outcomes · objective sleep null · multiple endpoints tested · cognition was the primary focus
Supports: subjective sleep-quality gain over placebo in healthy adults (industry-funded).
“Magnesium supplementation significantly improved reported sleep quality, with the active group showing a 32% increase compared to 16% in the placebo group (p = 0.034).”
Panel auditInternal validity: medium · scope of inference: Healthy adults taking a low-dose (80 mg) food-grown magnesium product.Key limitations: low elemental dose · PSQI improved in both arms · primary win on subjective item
Magnesium condition showed significant improvements vs placebo for sleep-quality and activity outcomes.
Panel auditInternal validity: medium · scope of inference: Adults with nonclinical insomnia symptoms taking a proprietary magnesium product.Key limitations: pilot · very small sample · proprietary formulation · some sleep scales nonsignificant
4 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus supports a modest, mainly subjective benefit but small effect sizes, sponsor funding, heterogeneous forms, and null objective/observational evidence keep it short of a robust verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Objective confirmation of subjective benefit. The signal is largely subjective and diverges from device data ([3]), raising the possibility of a reporting artefact. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered RCT with polysomnography as the primary endpoint alongside validated questionnaires.
Open question: Does any specific magnesium form improve sleep quality more than another, or is 'magnesium' too broad to license the claim? Why it is still open: The corpus pools L-threonate, bisglycinate, oxide and Food-Grown products with no head-to-head comparison ([1],[3],[4],[6],[7]).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19